Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Announced the Closing of US$11M in Seed Financing","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Giiant pharma"},{"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Giiant pharma"}]

Giiant pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept

Details:

Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.

Lead Product(s): GT-2108

Therapeutic Area: Gastroenterology Product Name: GT-2108

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Amplitude Ventures

Deal Size: $1.2 million Upfront Cash: Undisclosed

Deal Type: Financing June 30, 2021

ASK
US

Upload
your Pipeline Activity

Giiant pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Giiant Pharma inc Announced the Closing of US$11M in Seed Financing

Details:

The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.

Lead Product(s): GT-2108

Therapeutic Area: Gastroenterology Product Name: GT-2108

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Amplitude Ventures

Deal Size: $11.0 million Upfront Cash: Undisclosed

Deal Type: Financing May 19, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY